

Open Access Article

TRICHOGENIC EFFECT OF LOW LEVEL LASER THERAPY COMBINED WITH PLATELET-RICH PLASMA FOR THE MANAGEMENT OF ANDROGENETIC ALOPECIA

Maha Rafea Abo Eitta¹, Ahmed Sadek², Noha Abdelaziz Amer³, Nevien Samy¹, Noha Abdallah¹

¹Dermatology unit, Medical application of laser (MAL) department, National Institute of Laser and Enhanced Sciences, Cairo University, Giza, Egypt

²Cairo Hospital for Dermatology & Venereology (Al-Haud Al-Marsoud), Cairo, Egypt³Dermatology specialist, Minya El-Qamh General Hospital, Sharkia, Egypt

Corresponding author: Ahmed Sadek, Ph.D., M.Sc., Email: askdrsadek@gmail.com

Abstract

Background: Androgenetic alopecia is a very common hair disorder in men, Topical Minoxidil and more recently low-level light therapy and Platelet-rich plasma therapy have been used in the management of Androgenetic alopecia **Objectives:** To assess the Trichogenic effect of low-level light therapy combined with Platelet-rich plasma in the management of Androgenetic alopecia. **Patients and methods:** Forty seven patients with Androgenetic alopecia were subjected to Platelet-rich plasma therapy plus low-level light therapy, affected area of all patients were treated for three months and then follow up for another three months. Efficacy was evaluated using global photography, follisopic pictures analysis, answers for standardized hair growth questions and score of patient Gratification. **Results:** There was statistically significant improvement in diameter, vellus hair, terminal hair and density after treatment for three months although these improvements were decreased at three month after stoppage of treatment but still better than the baseline. **Conclusion** combination of low-level light therapy with Platelet-rich plasma could be a good treatment modality of Androgenetic alopecia. **Keywords:** Androgenetic alopecia, Low-level laser therapy, Platelet-rich plasma.

抽象的

背景：雄激素性脱发是男性非常常见的毛发疾病，局部用米诺地尔和最近的低强度光疗法和富血小板血浆疗法已用于治疗雄激素性脱发目的：评估低强度光的毛发生长效应结合富血小板血浆治疗雄激素性脱发。患者及方法：对47例雄激素性脱发患者进行富血小板血浆疗法加低强度光疗法，所有患者的患部均治疗3个月，再随访3个月。使用全局摄影、毛囊照片分析、标准化毛发生长问题的答案和患者满意度评分来评估疗效。结果：治疗三个月后，直径、

毳毛、终毛和密度有统计学意义的改善，尽管这些改善在停止治疗后三个月有所下降，但仍优于基线。结论 低强度光疗联合富血小板血浆治疗雄激素性脱发是一种较好的治疗方式。

关键词：雄激素性脱发，低强度激光治疗，富血小板血浆。

Introduction

Androgenetic alopecia (AGA) is a very widespread dermatological disorder in which hair of the scalp is gradually converted from terminal to vellus in reproducible pattern affecting both sex, this pathophysiology is known as miniaturization [1-3]. This is androgen-dependent in males, while in women it's better to use female pattern hair loss (FPHL) term than Androgenetic alopecia because there's no certain relationship between androgens and this pathology [4-6]. Management of AGA using Finasteride orally and Minoxidil topically has been approved by the Food and Drug Administration (FDA) and both of them generally give good results [7]. But sometimes patients who are experiencing ungratified response or complained of side effects ask about additional or alternative treatment. The efficacy of red light and laser therapy at wave length 660 nm has been approved for management of hair loss (HL) [8], and therefore light-emitting diodes (LEDs) as a phototherapy, has been widely used to enhance hair growth (HG) in AGA [9-10]. The combination between LLLT and LEDs improve the density of the hair through photobiomodulation and activation of the metabolism of hair follicles cells [11]. PRP is a relatively new option which provided good results in AGA. PRP which is an autologous preparation to obtain plasma containing highly concentrated platelets can provide a high quantity of more than 20 growth factors (GF). All of them have an important role in the biomolecular metabolism of the hair re-growth (HR-G) [12]. Many published studies approved that PRP either a monotherapy or in combination with other treatment is effective in management AGA [13]. The current study aimed to evaluate the Trichogenic effect of photobiomodulation combined with PRP in management of AGA.

Patients and Methods

This clinical study was performed in Dermatology out-patient clinic, NILES, Cairo University. We obtained the approval of the Dermatology Research Ethical Committee, NILES, Cairo University about this clinical study moreover all patients included in this study were informed about the benefit and side effects of this therapy and each of them signed a written consent, forty-seven adult male patients (age > 22 years) with grade II-IV AGA, as classified by the Norwood-Hamilton classification scale (14), were included in this study. Patients who had another cause of hair loss like anemia, thyroid disorders and poor nutrition also those with diseases of immunosuppression, platelet disorders, sepsis, cancer, uncompensated diabetes or patients who utilized topical or oral drugs for management of AGA in the previous year were excluded. Patients were asked about their special habits or life style to know if they are exposed to any factor can exacerbate AGA such as ultraviolet exposure or smoking. Diagnosis of AGA depended on a detailed medical history, clinical, and trichoscopy examination (Folliscope, Compare view, ver.1.5.09, CA -USA). Was used to assess the hair parameters, the hair density was assessed by counting the number of hairs within about 15mm² area which was the same area investigated either pre, post treatment and followed up according to a map for each patient, while

hair diameter was measured by calculating the mean value of the diameter of 5 hairs in this area. Also terminal to vellus ratio was measured.

Treatment Protocol


All included patients were treated by 4 sessions of PRP injections with 3 weeks apart combined with sessions of LLLT for 25 minutes using the iGROW1 helmet device (21 Lasers Diodes and 30 LEDs, 655nm red laser with output <math><5\text{mW}</math> CW and LED wave length range from 650 to 670 nm) 3 times per week not consecutive days for 3 months. Follow up for another 3 months after cessation of treatment was performed for all involved patients.

Assessment of Hair Growth Parameters


All patients were evaluated upon their initial visit, at 3 and 6 months from starting the treatment. Through Global clinical photography, Patients gratification and objectively by follisopic assessing the hair measures (hair density, terminal/vellus ratio and hair diameter) in this study PRP was prepared with the same technique as Verma, et al [15]. Patient gratification was determined as a very gratified, gratified, neutral and ungratified. Any side effects or complains from the therapy was reported.

Results

Forty seven patients were included and completed this clinical study. Age of the studied patients varied from 22 to 37 years with mean 33.15 years. Disease duration ranged from 1 to 16 year with median 14 years. About 53%, 38% and 9% had alopecia type III, II and IV respectively. Their demographic data are presented in table 1.



Pre	100.9/cm ² Terminal= 20Intermediate= 11Total= 31%T= 64.5%%I= 35.5%
Post	123.7/cm ² Terminal= 32Intermediate= 6Total= 38%T= 84.2%%I= 15.8%
Follow up	117.2/cm ² Terminal= 28Intermediate= 8Total= 36%T= 77.8%%I= 22.2%



Pre	1	0.082	0.063	0.084	0.085	0.056	0.06	StatsAV	0.07SD	0.01
Post	1	0.092	0.063	0.114	0.085	0.096	0.13	StatsAV	0.09SD	0.02
Follow up	1	0.082	0.073	0.114	0.065	0.066	0.12	StatsAV	0.08SD	0.03






Fig (3) Patients A and B, pre (baseline), post (3months after treatment) and follow up 3 months after stoppage of treatment



Pre	107.4/cm ² Terminal= 21Intermediate= 12Total= 33%T= 63.6%%I= 36.4%
Post	130.2/cm ² Terminal= 29Intermediate= 11Total= 40%T= 72.5%%I= 27.5%
Follow up	123.7/cm ² Terminal= 28Intermediate= 10Total= 38%T= 73.7%%I= 26.3%



Pre	1	0.072	0.073	0.064	0.115	0.076	0.07	StatsAV	0.08SD
	0.02								
Post	1	0.102	0.163	0.104	0.085	0.096	0.08	StatsAV	0.10SD
	0.03								
Follow up	1	0.122	0.113	0.064	0.115	0.086	0.08	StatsAV	0.09SD
	0.02								

Figure (4) Follicoscopic analysis of the same patients (A and B) hair density including terminal hair as green dots, vellus hair as red dots (magnification: $\times 50$) and hair diameter as turquoise rectangular (magnification $\times 200$)

Table 1: Distribution of the studied patients according to baseline data:

Parameter	N=47 (%)
Age (year): Mean SDRange	33.15 \pm 3.6 22 – 37
Duration (year):Median Range	14 1 – 16
Types:II IIIIV	18 (38.3) 25 (53.2) 4 (8.5)

Table 2: Disease-specific parameters before and after treatment

	Before treatment	After treatment for 3 months	Three months after stoppage of treatment	p
Diameter Mean \pm SD Range	0.068 \pm 0.007 0.06 – 0.08	0.11 \pm 0.009 0.09 – 0.12	0.09 \pm 0.01 0.08 – 0.11	<0.001**
Paired t	P1 <0.001**	P2 <0.001**	P3 <0.001**	
Vellus hair: Mean \pm SD Range	29.53 \pm 9.74 12.5 – 48.4	17.06 \pm 6.1 76.9 – 93.9	22.09 \pm 4.46 12.8 – 26.8	<0.001**

Paired t	P1 <0.001**	P2 <0.001**	P3 <0.001**	
Terminal hair:				
Mean ± SD	70.47±9.72	82.94±6.1	77.91±4.46	<0.001**
Range	51.6 – 87.5	0.769 – 0.939	73.2 – 87.2	
Paired t	P1 <0.001**	P2 <0.001**	P3 <0.001**	
Density(/cm2):				
Mean ± SD	109.36±14.69	128.34±16.78	120.93±15.66	<0.001**
Range	91.1 – 143.2	110.7 – 166	107.4 – 159.5	
Paired t	P1 <0.001**	P2 <0.001**	P3 <0.001**	

P for repeated measure ANOVA test *p<0.05 is statistically significant **p≤0.001 is statistically highly significant

p1 difference between values before treatment and after treatment for 3 months

p2 difference between values after treatment for 3 months and three months after stoppage of treatment

P3 difference between values before treatment and three months after stoppage of treatment

There was a significant increase in diameter of the hair after treatment for three months as compared to baseline level however the level showed significant decrease 3 months after stoppage of treatment. There was a significant increase in terminal hair and density after treatment for 3 months as compared to baseline level; however the level showed significant decrease three months after stoppage of treatment yet to levels significantly higher than baseline level. There was a significant decrease in vellus hair after treatment for 3 months as compared to baseline level, however the level showed significant increase three months after stoppage of treatment yet to levels significantly lower than baseline level as shown in table 2 and Figure 1, 2, 3,4. On studying the factors that could affect the response such as platelet count and duration of disease, we reported the following: There was a statistically significant positive correlation between platelet count and all of diameter, terminal hair and density after treatment for 3 months and three months after stoppage of treatment as shown in table 3. There was a statistically significant negative correlation between disease duration and diameter after treatment for 3 months and 3 months after stoppage of treatment. While, there was a statistically non-significant correlation between disease duration and either density, vellus or terminal hair after treatment for 3 months and 3 months after stoppage of treatment as shown in table 4. As regard patient gratification as shown in table 5, 34% and 36% of patients were very gratified and gratified with look of hair respectively. Regarding gratification with look of front of hair, 12.58% were very gratified and 55% were gratified. Only 19% think that treatment is non-effective while 40.4% and 40.4% think that treatment is fairly and very effective. About 40% and 47% described hair growth as markedly and moderately and increased. While 51.1% agreed with that bald spots getting smaller.(As shown in table 5).




Figure 1: multiple line graph showing change in the studied parameters before and after treatment




Figure 2: multiple line graph showing change in the diameter of hair before and after treatment

Table 3: Correlation between platelet count and the studied parameters

Parameter	Platelet count			
	After 3 months		Three months after stoppage	
	r	p	r	p
diameter	0.541	<0.001**	0.669	0.011*
Vellus hair	-0.467	0.001**	-0.559	0.001**
Terminal hair	0.467	0.001**	0.559	0.001**
Density	0.421	0.003*	0.365	0.012*

r Pearson correlation coefficient *p<0.05 is statistically significant **p≤0.001 is statistically highly significant

Table 4: Correlation between disease duration and the studied parameters

Parameter	Disease duration			
	After 3 months		Three months after stoppage	
	r	p	r	p
diameter	0.541	<0.001**	0.669	0.011*
Vellus hair	-0.467	0.001**	-0.559	0.001**
Terminal hair	0.467	0.001**	0.559	0.001**
Density	0.421	0.003*	0.365	0.012*

diameter	-0.468	<0.001**	-0.7	0.011*
Vellus hair	0.049	0.743	0.029	0.846
Terminal hair	-0.049	0.743	-0.029	0.846
Density	-0.02	0.896	0.021	0.889

r Pearson correlation coefficient *p<0.05 is statistically significant **p≤0.001 is statistically highly significant

Table 5: Distribution of the studied patients according to patient gratification

Variables	Items	N=47	%
Gratified with the look of hair generally	Ungratified	6	12.8
	Neutral	8	17
	Gratified	17	36.2
	Very gratified	16	34
Gratified with the look of the top of hair	Ungratified	6	12.8
	Neutral	7	14.9
	Gratified	25	53.2
	Very gratified	9	19.1
Gratified with the look of the front of hair	Ungratified	5	10.6
	Neutral	10	21.3
	Gratified	26	55.3
	Very gratified	6	12.8
What is your opinion about the effectiveness of this combination in management of your hair loss?	Not effective	9	19.2
	Fairly effective	19	40.4
	Very effective	19	40.4
What about the growth of your hair?	No change	0	0
	lightly increased	6	12.8
	Moderately increased	22	46.8
	Markedly increased	19	40.4
After treatment my bald spot improved and get smaller	Strongly disagree	0	0
	Disagree	6	12.8
	Neutral	6	12.8
	Agree	24	51.1
	Strongly agree	11	23.4

Discussion

AGA is the utmost etiology of men's hair loss as about fifty percent of males all over the world suffer from it [16]. It affects persons who have genetic susceptibility where gene expression is regulated by

binding of androgen like testosterone and dihydrotestosterone as its derivative to the receptor of nuclear androgenic [17]. The main component of the pathogenesis of this disorder is the abnormality of androgen signaling that result in disrupted activation of epithelial progenitor cell this lead to gradual and continuous conversion of susceptible hair follicles from terminal to vellus stage this process is called miniaturization [18-19]. Up to date transplantation of hair surgically, finasteride orally and Minoxidil topically are the most widely used modalities in management of AGA [16]. But not all patients obtain the desired results from these modalities as hair transplantation is expensive more ever the implanted hair is supplied from specific donor sites of the patients and sometimes there is scar at this sites, medical treatment need unlimited use and restricted by patient attachment [20]. Because of this, dermatologists look for another therapy which can give better result, LLLT is considered a new therapeutic modality and previous clinical studies recommended it for management of AGA in both sex either as a monotherapy or in combination with finasteride and Minoxidil [21]. PRP, a recent bioengineering technique which is the outcome of intensified work in the field of cell-based and tissue engineering therapy, which is determined as an autologous product of plasma with condensed platelets, it is rich with many various growth factors and cytokines, that can increase the body's intrinsic capability of repair and regeneration [22-23]. To the date of writing this manuscript, only one published study [24] assessed combined PRP and LLLT for management of AGA and demonstrated good results. That is why in this study we aim for further evaluation of the efficacy of LLLT combined with PRP in the treatment of AGA. Forty seven patients were included and were treated by 4 sessions of PRP injections with 3 weeks apart combined with sessions of LLLT for 25 minutes using the iGROW1 helmet device 3 times per week not consecutive days for 3 months and were followed for extra 3 months after last treatment session. We demonstrated significant increase in the density of terminal hair also significant decrease of vellus hair density after treatment for 3 months as compared to baseline level; however the level showed significant decrease three months after stoppage of treatment yet to levels significantly higher than baseline level. Due to the variations in published study designs, using either LLLT or PRP, we have contributed a difficulty in comparing our results with other studies except for that of Gentile et al. [24] who treated 23 patients with AGA (13 male +10 female) with LLLT using helmet Hair Gentrion® (DTS MG Co., Ltd., Seoul, Korea, #B108-147), two times per week for 24 weeks Combined with ANA-PRP 3 sessions 30 days apart, plus MN-T just before each PRP infiltration which was repeated every 15 days for 3 times. In spite of the difference of study protocol between this current study and Gentile et al study, both studies are in agreement that: the combination of LLLT with PRP is a good and safe modality in the management of AGA. This was clearly noticed by the statistically significant hair improvement (hair density, diameter) following treatment. This improvement may be contributed to the synergetic combined effect of LLLT and PRP. LLLT promote hair growth although the mechanism is still unclear, it is postulated that this action due to mitosis acceleration and also may be due to activation of follicular keratinocytes and stem cell, furthermore LLLT may change cellular metabolism as it photo dissociate the inhibitory nitric oxide from cytochrome c oxidase Unit four in mitochondrial respiratory chain lead to stimulation of production of ATP and activation of the cells [25-27]. Additionally subside of inflammation could be another mechanism of action of stimulation of hair growth by LLLT in AGA, as there is clinical

studies recommended that LLLT lower the level of proinflammatory cytokines and inflammatory mediators like prostaglandin E-2, on the other side it elevate the anti-inflammatory cytokines as transforming growth factor beta1 and interleukin 10 [28-34]. Stem cells which arise from the bulge area of the hair follicle express receptors that bind with the growth factors found in PRP this binding enhance hair regrowth by stimulating the proliferation of the hair follicle and emerge it into the anagen phase [34-35]. Moreover, these growth factors evoke a serial of chemical reactions that stimulate angiogenesis and enhance the adnexal structures like keratinocytes which is present in the outer root sheath and dermal papillae fibroblasts to secrete vascular endothelial growth factor(VEGF), the latter is linked with angiogenesis and anagen phase stimulation as it stimulate the growth of dermal structures either normal or pathological [36]. Activated autologous PRP (AA- PRP) up regulate β -catenin and fibroblast growth factor 7, signaling of AKT and also extracellular cellular associated kinase, this up regulation lead to dermal papillae proliferation [36]. That is why we used the activated autologous PRP in this current study. This was in agreement with Gentile et al (37) who compared between autologous non-activated PRP (ANA- PRP) and AA-PRP in management of AGA and concluded that both modalities resulted in good effect and significant improvement as regard hair parameters. This current study highlighted an important role of platelet count which affects the degree of improvement, which was clearly obvious by the positive correlation between platelet count and hair regrowth parameters, in this concern this current study is in agreement with Verma and his coworkers who treated 15 patients with AGA with PRP and concluded that PRP with higher platelets count give better clinical improvement than PRP with low platelet count [15]. Also, we demonstrated that whatever the duration of AGA, this combined modality of treatment has non-significant positive improvement on hair density and vellus/terminal hair ratio. Both are needed for further studies. As regard patient gratification which is the first priority at health system, we reported 70% of the patients were gratified to very gratified and this can determined the advantages of the combined treatment modality with no side effects.

Conclusion

Low level laser therapy combined with PRP could be a safe and good modality for the management of AGA as determined by the clinical and follisopic analysis

References

- (1) Galadari H, Shivakumar S, Lotti T, et al. Low-level laser therapy and narrative review of other treatment modalities in Androgenetic alopecia. *Lasers Med Sci.* 2020. <https://doi.org/10.1007/s10103-020-02994-4>.
- (2) Goren A, Sharma A, Dhurat R, et al. Low-dose daily aspirin reduces topical Minoxidil efficacy in Androgenetic alopecia patients. *Dermatol Ther.* 2018; 31(6):e12741. doi: 10.1111/dth.12741.
- (3) Yi Y, Qiu J, Jia J, et al. Severity of Androgenetic alopecia associated with poor sleeping habits and carnivorous eating and junk food consumption—a web-based investigation of male pattern hair loss in China. *Dermatol Ther.* 2020; 14:e13273. doi: 10.1111/dth.13273.
- (4) Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of

Androgenetic alopecia: a systematic review. *Dermatol Ther.* 2020; 33(1):e13202. doi: 10.1111/dth.13202.

(5) Olsen EA. Female pattern hair loss. *J Am Acad Dermatol.* 2001; 45:S70-80. doi: 10.1067/mjd.2001.117426.

(6) Ramos PM, Santos LDN, Mesinkovska NA, Goren A, Miot HA. Can we halt male Androgenetic alopecia progression without ant androgenic drugs? *Dermatol Ther.* 2020; 33(1):e13197. PMID: 31846191 DOI: [10.1111/dth.13197](https://doi.org/10.1111/dth.13197).

(7) Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, Trakatelli M, Finner A, Kiesewetter F, Trüeb R, Rzany B. Evidence-based (S3) guideline for the treatment of Androgenetic alopecia in women and in men. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft.* 2011 Oct; 9:S1- 57. PMID: 21980982 DOI: [10.1111/j.1610-0379.2011.07802.x](https://doi.org/10.1111/j.1610-0379.2011.07802.x)

(8) Kim WS, Calderhead RG. Is light-emitting diode phototherapy (LED-LLLT) really effective? *Laser Ther.* 2011; 20:205–15. doi: [10.5978/islsm.20.205](https://doi.org/10.5978/islsm.20.205)

(9) Avci P, Gupta GK, Clark J, et al. Low-Level Laser (Light) Therapy (LLLT) for Treatment of Hair Loss.

Lasers Surg Med. 2013; 9999:1. PMID: 23970445 PMCID: PMC3944668 DOI: [10.1002/lsm.22170](https://doi.org/10.1002/lsm.22170)

(10) Suchonwanit P, Chalermroj N, Khunkhet S. Low-level laser therapy for the treatment of Androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device controlled trial. *Lasers Med Sci* 2019 Aug; 34(6):1107-1114 doi: [10.1007/s10103-018-02699-9](https://doi.org/10.1007/s10103-018-02699-9). Epub 2018 Dec 19.

(11) Lanza fame RJ, Blanche RR, Chiacchierini RP, et al. The growth of human scalp hair in females using visible red-light laser and LED sources. *Lasers Surg Med.* 2014; 46:601–7. doi: [10.1002/lsm.22277](https://doi.org/10.1002/lsm.22277)

(12) Gentile P, Calabrese C, De Angelis B, et al. Impact of the Different Preparation Methods to Obtain Autologous Non-Activated Platelet-Rich Plasma (A-PRP) and Activated Platelet-Rich Plasma (AA-PRP) in Plastic Surgery: Wound Healing and Hair Regrowth Evaluation. *Int J Mol Sci.* 2020; 9:21(2). doi: [10.3390/ijms21020431](https://doi.org/10.3390/ijms21020431)

(13) Stevens J, Khetarpal S. Platelet-rich plasma for Androgenetic alopecia: a review of the literature and proposed treatment protocol. *Int J Women's Dermatol* 2019; 5(1):46–51. doi:[10.1016/j.ijwd.2018.08.004](https://doi.org/10.1016/j.ijwd.2018.08.004).

(14) Gupta M, Mysore V. Classifications of patterned hair loss: a review. *Journal of cutaneous and aesthetic surgery.* 2016 Jan; 9(1):3. PMID: 27081243 PMCID: PMC4812885 DOI: [10.4103/0974-2077.178536](https://doi.org/10.4103/0974-2077.178536)

(15) Verma K, Tegta GR, Verma G, Gupta M, Negi A, Sharma R. A study to compare the efficacy of platelet rich plasma and Minoxidil therapy for the treatment of Androgenetic alopecia. *Int j Trichology.* 2019 Mar; 11(2):68.

PMID: 31007475 PMCID: PMC6463452 DOI: [10.4103/ijt.ijt_64_18](https://doi.org/10.4103/ijt.ijt_64_18)

(16) Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. *Endocrinol Metab Clin North Am.* 2007; 36(2):379–398. PMID: 17543725 DOI: [10.1016/j.ecl.2007.03.004](https://doi.org/10.1016/j.ecl.2007.03.004)

(17) Ghanaat M. Types of hair loss and treatment options, including the novel low-level light

- therapy and its proposed mechanism. *South Med J.* 2010; 103(9):917–921. PMID: 20689478 DOI: 10.1097/SMJ.0b013e3181ebcf71
- (18) Itami S, Inui S. Role of androgen in mesenchymal epithelial interactions in human hair follicle. *J Invest Dermatol Symp Proc.* 2005; 10(3):209–211. PMID: 16382666 DOI: 10.1111/j.1087-0024.2005.10107.x
- (19) Hoffmann R, Happle R. Current understanding of Androgenetic alopecia. Part I: Etiopathogenesis. *Eur J Dermatol.* 2000; 10(4):319–327. PMID: 10846263
- (20) Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. *J Am Acad Dermatol.* 2008; 59(4):547–566. Quiz 567–548. PMID: 18793935 DOI: 10.1016/j.jaad.2008.07.001
- (21) Darwin E, Heyes A, Hirt PA, Wikramanayake TC, Jimenez JJ. Low-level laser therapy for the treatment of androgenic alopecia: a review. *Lasers Med Sci.* 2018 Feb; 33(2):425–434. doi: 10.1007/s10103-017-2385-5. Epub 2017 Dec 21. PMID: 29270707.
- (22) Marwah M, Godse K, Patil S, Nadkarni N: Is there sufficient research data to use platelet rich plasma in dermatology? *Int J Trichology* 2014; 6: 35–36. PMID: 25114455 PMCID: PMC4124695 DOI: 10.4103/0974-7753.136763
- (23) Dhillon RS, Schwarz EM, Maloney MD: Platelet-rich plasma therapy – future or trend? *Arthritis Res Ther* 2012; 14: 21 PMID: 22894643 PMCID: PMC3580559 DOI: 10.1186/ar3914
- (24) Gentile P, Dionisi L, Pizzicannella J, de Angelis B, de Fazio D, Garcovich S. A randomized blinded retrospective study: the combined use of micro-needling technique, low-level laser therapy and autologous non-activated platelet-rich plasma improves hair re-growth in patients with androgenic alopecia. *Expert Opin Biol Ther.* 2020 Sep; 20(9):1099–1109. doi: 10.1080/14712598.2020.1797676. Epub 2020 Jul 27. PMID: 32678725.
- (25) Lubart R, Eichler M, Lavi R, Friedman H, Shainberg A. Low energy laser irradiation promotes cellular redox activity. *Photomed Laser Surg.* 2005; 23(1):3–9. PMID: 15782024 DOI: 10.1089/pho.2005.23.3
- (26) Eells JT, Wong-Riley MT, Ver Hoeve J, Henry M, Buchman EV, Kane MP, et al. Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy. *Mitochondrion.* 2004; 4(5–6):559–67. PMID: 16120414 DOI: 10.1016/j.mito.2004.07.033
- (27) Pastore D, Greco M, Passarella S. Specific helium-neon laser sensitivity of the purified cytochrome c oxidase. *Int J Radiat Biol.* 2000; 76(6):863–70. PMID: 10902741 DOI: 10.1080/09553000050029020
- (28) Arany PR, Nayak RS, Hallikerimath S, Limaye AM, Kale AD, Kondaiah P. Activation of latent TGF- β 1 by low-power laser in vitro correlates with increased TGF- β 1 levels in laser enhanced oral wound healing. *Wound Repair Regen.* 2007; 15(6):866–74. PMID: 18028135 DOI: 10.1111/j.1524-475X.2007.00306.x
- (29) de Lima FM, Villaverde AB, Albertini R, Correa JC, Carvalho RL, Munin E, et al. Dual effect of low-level laser therapy (LLLT) on the acute lung inflammation induced by intestinal ischemia and reperfusion: action on anti- and pro-inflammatory cytokines. *Lasers Surg Med.* 2011; 43(5):410–

20. PMID: 21674546 DOI: 10.1002/lsm.21053

(30) Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. *Br J Dermatol.* 1992; 127(3):239–46. PMID: 1390168 DOI: 10.1111/j.1365-2133.1992.tb00121.x

(31) Mafra de Lima F, Villaverde AB, Salgado MA, Castro-Faria-Neto HC, Munin E, Albertini R, et al. Low intensity laser therapy (LLL-T) in vivo acts on the Neutrophils recruitment and Chemokines/ cytokines levels in a model of acute pulmonary inflammation induced by aerosol of lipopolysaccharide from *Escherichia coli* in rat. *J Photochem Photobiol B.* 2010; 101(3): 271–8. PMID: 20728373 DOI: 10.1016/j.jphotobiol.2010.07.012

(32) Magro CM, Rossi A, Poe J, Manhas-Bhutani S, Sadick N. The role of inflammation and immunity in the pathogenesis of Androgenetic alopecia. *J Drugs Dermatol.* 2011; 10(12):1404–11. PMID: 22134564

(33) Sakurai Y, Yamaguchi M, Abiko Y. Inhibitory effect of low-level laser irradiation on LPS-stimulated prostaglandin E2 production and cyclooxygenase-2 in human gingival fibroblasts. *Eur J Oral Sci.* 2000; 108(1):29– 34. PMID: 10706474 DOI: 10.1034/j.1600-0722.2000.00783.x

(34) Akiyama M, Smith LT, Holbrook KA: Growth factor and growth factor receptor localization in the hair follicle bulge and associated tissue in human fetus. *J Invest Dermatol* 1996; 106: 391–396. PMID: 8648166 DOI: 10.1111/1523-1747.ep12343381

(35) Gkini M-A, Kouskoukis A-E, Tripsianis G, Rigopoulos D, Kouskoukis K: Study of platelet-rich plasma injections in the treatment of Androgenetic alopecia through a one-year period. *J Cutan Aesthet Surg* 2014; 7: 213– 219. PMID: 25722600 PMCID: PMC4338465, doi: 10.4103/0974-2077.150743

(36) Cervelli V, Garcovich S, Bielli A, Cervelli G, Curcio BC, Scioli MG, Orlandi A, Gentile P: The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: clinical and histo Morphometric evaluation. *Biomed Res Int* 2014; 2014: 760709.

(37) Gentile P, Cole JP, Cole MA, et al. Evaluation of Not-Activated and Activated PRP in Hair Loss Treatment: Role of Growth Factor and Cytokine Concentrations Obtained by Different Collection Systems. *Int. J. Mol. Sci.* 2017;18: 408. PMID: 28216604 PMCID: PMC5343942, doi: 10.3390/ijms18020408